2 studies found for:    SGN-CD33A
Show Display Options
Rank Status Study
1 Recruiting A Safety Study of SGN-CD33A in AML Patients
Conditions: Acute Myelogenous Leukemia;   Acute Myeloid Leukemia;   Acute Promyelocytic Leukemia
Interventions: Drug: HMA;   Drug: SGN-CD33A
2 Recruiting A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
Conditions: Acute Myeloid Leukemia;   Acute Myelogenous Leukemia
Interventions: Drug: Standard dose cytarabine for induction;   Drug: SGN-CD33A;   Drug: Daunorubicin;   Drug: High dose cytarabine for consolidation

Indicates status has not been verified in more than two years